Aliases & Classifications for Vascular Dementia

MalaCards integrated aliases for Vascular Dementia:

Name: Vascular Dementia 12 15 17 33
Multi-Infarct Dementia 75 54 72 33
Dementia, Vascular 75 44 72
Vascular Dementia, Susceptibility to 6
Dementia - Multi-Infarct 54
Dementia, Multi-Infarct 44
Multi Infarct Dementia 12
Multifocal Dementia 12
Dementia Vascular 55

Classifications:



External Ids:

Disease Ontology 12 DOID:8725
ICD9CM 35 290.4
SNOMED-CT 68 56267009
UMLS 72 C0011263 C0011269

Summaries for Vascular Dementia

NINDS : 54 Multi-infarct dementia (MID) is a common cause of memory loss in the elderly.  MID is caused by multiple strokes (disruption of blood flow to the brain).  Disruption of blood flow leads to damaged brain tissue.  Some of these strokes may occur without noticeable clinical symptoms. Doctors refer to these as “silent strokes.”  An individual having a silent stroke may not even know it is happening, but over time, as more areas of the brain are damaged and more small blood vessels are blocked, the symptoms of MID begin to appear.  MID can be diagnosed by an MRI or CT of the brain, along with a neurological examination. Symptoms include confusion or problems with short-term memory; wandering, or getting lost in familiar places; walking with rapid, shuffling steps; losing bladder or bowel control; laughing or crying inappropriately; having difficulty following instructions; and having problems counting money and making monetary transactions.  MID, which typically begins between the ages of 60 and 75, affects men more often than women. Because the symptoms of MID are so similar to Alzheimer’s disease, it can be difficult for a doctor to make a firm diagnosis.  Since the diseases often occur together, making a single diagnosis of one or the other is even more problematic.

MalaCards based summary : Vascular Dementia, also known as multi-infarct dementia, is related to binswanger's disease and dementia. An important gene associated with Vascular Dementia is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Selenium Micronutrient Network and Neuroscience. The drugs Metformin and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and endothelial, and related phenotypes are homeostasis/metabolism and behavior/neurological

Disease Ontology : 12 A dementia that involves impairments in cognitive function caused by problems in blood vessels that feed the brain.

Wikipedia : 75 Vascular dementia is dementia caused by problems in the supply of blood to the brain, typically a series... more...

Related Diseases for Vascular Dementia

Diseases related to Vascular Dementia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 287)
# Related Disease Score Top Affiliating Genes
1 binswanger's disease 32.1 NOTCH3 MAPT APP APOE ACHE
2 dementia 31.0 TNF PSEN1 NOTCH3 MAPT CHAT BCHE
3 sleep apnea 30.8 TNF APOE ACE
4 carotid stenosis 30.8 TNF MTHFR APOE ACE
5 atherosclerosis susceptibility 30.8 TNF PON1 APOE
6 arteriosclerosis 30.6 PON1 APOE ACE
7 aphasia 30.6 PSEN1 MAPT APP APOE
8 behavioral variant of frontotemporal dementia 30.6 PSEN1 MAPT
9 coronary heart disease 1 30.5 PON1 MTHFR APOE ACE
10 head injury 30.4 CHAT APOE
11 nominal aphasia 30.4 PSEN1 MAPT
12 alzheimer disease 4 30.4 PSEN1 APOE
13 frontotemporal dementia 30.3 PSEN1 MAPT APP APOE ACHE
14 cerebral atherosclerosis 30.3 MTHFR APOE ACE
15 amnestic disorder 30.3 PSEN1 CHAT BCHE ACHE
16 semantic dementia 30.2 PSEN1 MAPT APOE
17 migraine with or without aura 1 30.2 TNF NOTCH3 MTHFR
18 gait apraxia 30.1 PSEN1 APP APOE
19 alexia 29.9 PSEN1 MBP APOE
20 ideomotor apraxia 29.9 MBP MAPT
21 migraine with aura 29.9 NOTCH3 MTHFR ACE
22 alzheimer disease 29.9 TNF SERPINA3 PSEN1 MAPT CST3 CHAT
23 supranuclear palsy, progressive, 1 29.9 MAPT CHAT APP APOE ACHE
24 parkinson disease, late-onset 29.8 MAPT CHAT APP APOE ACHE
25 vascular disease 29.8 VEGFA TNF PON1 MTHFR CST3 APOE
26 ischemia 29.7 VEGFA PON1 APP ACE
27 brain injury 29.7 MBP MAPT APOE
28 amyloidosis 29.7 PSEN1 CST3 APP APOE
29 hydrocephalus 29.7 MBP MAPT APP APOE
30 dementia, lewy body 29.7 PSEN1 MAPT BCHE APP APOE ACHE
31 creutzfeldt-jakob disease 29.7 SERPINA3 MAPT CST3 APOE
32 cerebrovascular disease 29.6 TNF PON1 NOTCH3 MTHFR MAPT APP
33 pick disease of brain 29.5 PSEN1 MAPT CHAT APP APOE
34 cerebral amyloid angiopathy, cst3-related 29.5 SERPINA3 PSEN1 MAPT CST3 APP APOE
35 arteries, anomalies of 29.4 VEGFA TNF PON1 APOE ACE
36 agraphia 29.0 PSEN1 MBP MAPT BCHE ACHE
37 myocardial infarction 28.5 VEGFA TNF PON1 MTHFR CST3 APOE
38 stroke, ischemic 28.4 PON1 NOTCH3 MTHFR MBP CST3 APOE
39 amyotrophic lateral sclerosis 1 27.5 PSEN1 PON1 NEFL MAPT CST3 CHAT
40 subcortical arteriosclerotic encephalopathy 11.6
41 cerebral arteriosclerosis 11.6
42 dementia - subcortical 11.5
43 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 11.2
44 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2 10.9
45 moderate and severe traumatic brain injury 10.7 APOE ACE
46 simultanagnosia 10.7 MAPT APOE
47 posterior cortical atrophy 10.7 MAPT APOE
48 dementia pugilistica 10.6
49 uveoparotid fever 10.6 TNF ACE
50 subacute cutaneous lupus erythematosus 10.6 TNF ACE

Comorbidity relations with Vascular Dementia via Phenotypic Disease Network (PDN):


Acute Cystitis Cerebral Atherosclerosis
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Vascular Dementia:



Diseases related to Vascular Dementia

Symptoms & Phenotypes for Vascular Dementia

MGI Mouse Phenotypes related to Vascular Dementia:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.39 ACE ACHE APOE APP BCHE CHAT
2 behavior/neurological MP:0005386 10.37 ACE ACHE APOE APP CHAT MAPT
3 growth/size/body region MP:0005378 10.31 ACE ACHE APOE APP CHAT MAPT
4 mortality/aging MP:0010768 10.3 ACE ACHE APOE APP BCHE CHAT
5 cardiovascular system MP:0005385 10.29 ACE APOE APP CHAT CST3 MAPT
6 hematopoietic system MP:0005397 10.22 ACE ACHE APOE APP MAPT MBP
7 nervous system MP:0003631 10.21 ACHE APOE APP CHAT CST3 MAPT
8 integument MP:0010771 10.15 APOE APP MAPT MTHFR NOTCH3 PSEN1
9 muscle MP:0005369 10.13 ACHE APOE APP CHAT CST3 MAPT
10 reproductive system MP:0005389 9.97 ACE ACHE APOE APP BCHE CHAT
11 limbs/digits/tail MP:0005371 9.95 APOE CHAT MTHFR PSEN1 TNF VEGFA
12 neoplasm MP:0002006 9.88 ACE CST3 MAPT NOTCH3 TNF VEGFA
13 no phenotypic analysis MP:0003012 9.87 ACHE APOE APP MAPT MTHFR TNF
14 normal MP:0002873 9.86 APP CHAT MAPT MBP NEFL NOTCH3
15 respiratory system MP:0005388 9.5 ACHE APOE CHAT NOTCH3 PSEN1 TNF
16 vision/eye MP:0005391 9.32 ACHE APOE CHAT MAPT MBP MTHFR

Drugs & Therapeutics for Vascular Dementia

Drugs for Vascular Dementia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 232)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 4091 14219
2
tannic acid Approved Phase 4 1401-55-4
3
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
4
Acetaminophen Approved Phase 4 103-90-2 1983
5
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
6
Donepezil Approved Phase 4 120014-06-4 3152
7
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
8
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
9
Galantamine Approved Phase 4 357-70-0 9651
10
Amlodipine Approved Phase 4 88150-42-9 2162
11
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
12
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
13
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
14
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
15
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
16
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
17
Enalaprilat Approved Phase 4 76420-72-9 6917719
18
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
19
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 130881 158781
20
Ramipril Approved Phase 4 87333-19-5 5362129
21
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
22
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
23
Doxazosin Approved Phase 4 74191-85-8 3157
24
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
25
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
26
Manidipine Approved, Investigational Phase 4 89226-50-6
27
Atenolol Approved Phase 4 29122-68-7 2249
28
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
29
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
30
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
31
Choline Approved, Nutraceutical Phase 4 62-49-7 305
32
Candesartan Experimental Phase 4 139481-59-7 2541
33
Corticosterone Experimental Phase 4 50-22-6 5753
34 Parasympatholytics Phase 4
35 Muscarinic Antagonists Phase 4
36 Cholinergic Antagonists Phase 4
37 insulin Phase 4
38 Insulin, Globin Zinc Phase 4
39 Hypoglycemic Agents Phase 4
40 Narcotics Phase 4
41 Peripheral Nervous System Agents Phase 4
42 Narcotic Antagonists Phase 4
43 Antipyretics Phase 4
44 Analgesics, Opioid Phase 4
45 Neurotransmitter Agents Phase 4
46 Protective Agents Phase 4
47 Nootropic Agents Phase 4
48 Cyclooxygenase Inhibitors Phase 4
49 Fibrinolytic Agents Phase 4
50 Respiratory System Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 169)
# Name Status NCT ID Phase Drugs
1 Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
2 A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery. Unknown status NCT00196703 Phase 4 memantine
3 Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial Unknown status NCT02409238 Phase 4 Metformin
4 Efficacy of Pain Treatment on Depression in Patients With Dementia. A Randomized Clinical Trial. Completed NCT02267057 Phase 4 Paracetamol;Buprenorphine;Paracetamol placebo;Buprenorphine placebo
5 Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Completed NCT00847860 Phase 4 Cilostazol;Aspirin
6 An Open Label Study on the Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia Completed NCT00165763 Phase 4 donepezil hydrochloride (Aricept)
7 A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Completed NCT00947531 Phase 4 Cerebrolysin;0.9% Saline Solution
8 A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery. Completed NCT00640198 Phase 4 memantine;memantine;placebo
9 Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT) Completed NCT00385684 Phase 4 hydrocodone/APAP w placebo PRN;hydrocodone/APAP;placebo with hydrocodone/APAP PRN
10 A Randomized, Double-blind, Placebo-controlled Phase IV Trial for an Evaluation of the Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no Dementia Completed NCT01363648 Phase 4 choline alfoscerate;placebo (for choline alphoscerate)
11 Treatment With Donepezil of Chronic Aphasia and Sensorimotor Deficits Associated to Cerebrovascular Accidents: a Double-Blind,Placebo-Controlled, Randomized Parallel Trial. Completed NCT00196690 Phase 4 Donepezil
12 Preventing Post-Operative Cognitive Decline Completed NCT00182845 Phase 4 Donepezil
13 Donepezil/ Galantamine in the Treatment of Post-stroke Cognitively Impaired Rehabilitating Elderly Completed NCT00227994 Phase 4 Galantamine;Donepezil
14 Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment Completed NCT00741585 Phase 4 Any antihypertensive medication alone or in combination;Any antihypertensive medication alone or in combination
15 Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
16 Clinical Observation for the Therapeutic Effect of mNGF on Cognitive Decline in Cerebral Small Vessel Disease Not yet recruiting NCT04041349 Phase 4 mouse nerve growth factor
17 Symptomatic Treatment of Vascular Cognitive Impairment Unknown status NCT02098824 Phase 2, Phase 3 Galantamine;Methylphenidate;Placebo
18 Evaluating the Effects of Music Interventions on Hospitalised People With Dementia Unknown status NCT00448318 Phase 2, Phase 3
19 Donepezil as Add-On Treatment of Psychotic Symptoms in Patients With Dementia of the Alzheimer's Type Unknown status NCT00190021 Phase 3 donepezil
20 Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed NCT00099216 Phase 3 Rivastigmine
21 An Open-label Extension to Evaluate the Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed NCT00130338 Phase 3 Rivastigmine
22 A 24-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy, Safety and Tolerability of Donepezil Hydrochloride (E2020) in Patients With Dementia Associated With Cerebrovascular Disease Completed NCT00165737 Phase 3 Donepezil Hydrochloride
23 A Randomized 26-Week, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia Completed NCT00035191 Phase 3 galantamine
24 A Multicenter, Double-Blind, Randomized, Comparison of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) and Placebo in the Treatment of Agitation Associated With Dementia. Completed NCT00621647 Phase 3 Quetiapine Fumarate;Quetiapine Fumarate;Placebo
25 A Phase III, Multicenter, Randomized, Double-blind, Positive /Placebo Controlled, Parallel, Three Arms Study of Tianzhi Granule in Mild to Moderate Vascular Dementia Completed NCT02453932 Phase 3 Tianzhi granule and placebo identified to donepezil;Donepezil and placebo identified to Tianzhi granule;Placebo
26 The Safety and Efficacy of Galantamine in the Treatment of Vascular and Mixed Dementia Completed NCT00261573 Phase 3 galantamine hydrobromide
27 Risperidone in the Treatment of Behavioural and Psychological Signs and Symptoms in Dementia (BPSSD): a Multicentre, Double-blind, Placebo-controlled Parallel-group Trial Completed NCT00249158 Phase 3 Risperidone
28 GEHC Has Decided Not to Provide This Detail But Will Rely on the Brief Title Completed NCT00209456 Phase 3 DatSCAN
29 A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone for Treatment of Behavioral Disturbances in Subjects With Dementia Completed NCT00253123 Phase 3 risperidone
30 Risperidone in the Treatment of Behavioral Disturbances in Demented Patients: an International, Multicenter, Placebo-controlled, Double-blind, Parallel-group Trial Using Haloperidol as Internal Reference Completed NCT00249145 Phase 3 risperidone
31 Serotonergic Pharmacotherapy for Agitation of Dementia Completed NCT00009204 Phase 3 Citalopram [Celexa];Perphenazine [Trilafon]
32 Ginkgo Biloba Prevention Trial in Older Individuals Completed NCT00010803 Phase 3 Ginkgo biloba;Placebo
33 Effect of Administration of Combination Metformine/Inulin Versus Metformine on Patients With Prostate Benign Hyperplasia and Metabolic Syndrome Syndrome Completed NCT02778776 Phase 3 Metformin
34 Effects of Dalfampridine on Cognition in Multiple Sclerosis Completed NCT02006160 Phase 2, Phase 3 dalfampridine;placebo
35 Multi-center Open Comparative Randomized Study of Efficacy and Safety of Akatinol Memantine 20 mg (Single-doses) vs. Akatinol Memantine 10 mg (Double-doses) in Patients With Moderate and Moderately Severe Vascular Dementia Recruiting NCT03986424 Phase 3 Akatinol Memantine 20 mg;Akatinol Memantine 10 mg
36 A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel, and Multi-centre Study to Evaluate the Clinical Efficacy and Safety of SaiLuoTong (SLT) in the Treatment of Vascular Dementia Recruiting NCT03789760 Phase 3 SaiLuoTong capsule;placebo
37 The Role of Palliative Care Interventions to Reduce Circadian Rhythm Disorders in Persons With Dementia: The Healthy Patterns Study Recruiting NCT03682185 Phase 3
38 A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis Recruiting NCT03325556 Phase 3 Placebo;Pimavanserin 34 mg;Pimavanserin 20 mg
39 Exercise and Intensive Vascular Risk Reduction in Preventing Dementia Recruiting NCT02913664 Phase 2, Phase 3 Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine);Atorvastatin
40 MIND Diet Intervention to Prevent Alzheimer's Disease Active, not recruiting NCT02817074 Phase 3
41 A Multi-center, Random, Double Blind and Placebo Control Phase III Clinical Study on the Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia Not yet recruiting NCT03804229 Phase 3 Butylphthalide soft capsule;Placebo soft capsule
42 Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study Not yet recruiting NCT03785067 Phase 3 telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg;Placebo oral capsule
43 An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia Terminated NCT00174382 Phase 3 Donepezil
44 Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity in Normal and Subcortical Vascular Cognitive Impairment Subjects Unknown status NCT01466543 Phase 2 Zydena (Udenafil);Placebo
45 Phase II, Randomized, Crossover, Single Blind, Safety Trial of DABIGATRAN Versus ASA for Preventing Ischaemic Brain Lesions in Patients Affected by CADASIL Unknown status NCT01361763 Phase 2 Dabigatran;Antiplatelets
46 Phase 2 Clinical Trial of SaiLuoTong Capsule for Vascular Dementia:A 26-week, Multicentre, Randomized, Double -Blind, Placebo-controlled Trial With a 26-week Open-label Extension Unknown status NCT01978730 Phase 2 high dose group of SaiLuoTong capsule;low dose group of SaiLuoTong;the control group
47 A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia Completed NCT02886494 Phase 2 BAC;Matched placebo
48 The Safety and Efficacy of Fufangdanshen Tablets in Treatment of Mild to Moderate Vascular Dementia: a 24-week, Double Blind, Randomized, Parallel,Placebo Controlled Trial. Completed NCT01761227 Phase 2 Fufangdanshen Tablets;Placebo
49 A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Parallel, Comparative, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency) Completed NCT01475578 Phase 2 STA-1;Ergoloid Mesylates tablet
50 A Phase II Trial to Study the Effect of Metformin on AD Biomarkers: A Randomized Placebo Controlled Crossover Pilot Study of Metformin Effects on Cognitive, Physiological and Biochemical Biomarkers of MCI and Dementia Due to AD Completed NCT01965756 Phase 2 Metformin;Placebos

Search NIH Clinical Center for Vascular Dementia

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Donepezil

Cochrane evidence based reviews: dementia, vascular

Genetic Tests for Vascular Dementia

Anatomical Context for Vascular Dementia

MalaCards organs/tissues related to Vascular Dementia:

41
Brain, Testes, Endothelial, Cortex, Heart, Temporal Lobe, Kidney

Publications for Vascular Dementia

Articles related to Vascular Dementia:

(show top 50) (show all 6733)
# Title Authors PMID Year
1
Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimer's disease and vascular dementia: a case-control study. 9 38 71
11273064 2001
2
TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels. 38 71
15895461 2005
3
Differences between clinical subspecialties in the outpatient evaluation and treatment of dementia in an academic medical center. 9 38
20110698 2010
4
Vascular dementia and Alzheimer's disease - are we in a dead-end road? 9 38
20173341 2010
5
Increased binding to 5-HT1A and 5-HT2A receptors is associated with large vessel infarction and relative preservation of cognition. 9 38
19433439 2009
6
Neuropathological correlates of temporal pole white matter hyperintensities in CADASIL. 9 38
19359623 2009
7
Association between a genetic variant of the alpha-7 nicotinic acetylcholine receptor subunit and four types of dementia. 9 38
19641318 2009
8
Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. 9 38
19221426 2009
9
Choline acetyltransferase activity in vascular dementia and stroke. 9 38
19776575 2009
10
Sporadic vascular dementia as clinical presentation of a new missense mutation within exon 7 of NOTCH3 gene. 9 38
18499132 2008
11
Enhanced L-arginine-induced vasoreactivity suggests endothelial dysfunction in CADASIL. 9 38
18537053 2008
12
Galantamine and carbon monoxide protect brain microvascular endothelial cells by heme oxygenase-1 induction. 9 38
18174021 2008
13
Lack of association between apolipoprotein E polymorphism and vascular dementia in Koreans. 9 38
18287165 2008
14
What is the relationship among atherosclerosis markers, apolipoprotein E polymorphism and dementia? 9 38
17539949 2007
15
Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins. 9 38
17395712 2007
16
Hippocampal sclerosis dementia differs from hippocampal sclerosis in frontal lobe degeneration. 9 38
17195931 2007
17
Presenilin gene predisposes to late-onset degenerative but not vascular dementia: a comparative study of PS1 and ApoE genes in a North Indian Cohort. 9 38
17627113 2007
18
Absence of association between codon 129 and 219 polymorphisms of the prion protein gene and vascular dementia. 9 38
17570906 2007
19
Apolipoprotein E genotypes in hospitalized elderly patients with vascular dementia. 9 38
17374951 2007
20
Treatment of vascular dementia and vascular cognitive impairment. 9 38
17215726 2007
21
Cortical neuronal apoptosis in CADASIL. 9 38
17008611 2006
22
Diabetes mellitus and dementia. 9 38
17110895 2006
23
Apolipoprotein E, angiotensin-converting enzyme and kallikrein gene polymorphisms and the risk of Alzheimer's disease and vascular dementia. 9 38
16465461 2006
24
Interventions for heart disease and their effects on Alzheimer's disease. 9 38
16945215 2006
25
Lipid metabolism in cognitive decline and dementia. 9 38
16410024 2006
26
Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. 9 38
16870640 2006
27
Cognitive frailty: Predementia syndrome and vascular risk factors. 9 38
16023766 2006
28
Haplotype analysis of single nucleotide polymorphisms in VEGF gene for vascular dementia. 9 38
16583410 2006
29
[Expression levels of APP and PS1 genes in patients with Alzheimer's disease]. 9 38
16735229 2006
30
Differential deposition of amyloid beta peptides in cerebral amyloid angiopathy associated with Alzheimer's disease and vascular dementia. 9 38
16555084 2006
31
Cerebrovascular disease in the elderly: lipoprotein metabolism and cognitive decline. 9 38
16702784 2006
32
Treating vascular risk factors and maintaining vascular health: is this the way towards successful cognitive ageing and preventing cognitive decline? 9 38
16461472 2006
33
Two novel mutations of the NOTCH3 gene in Korean patients with CADASIL. 9 38
16256149 2006
34
Apolipoprotein E epsilon4 allele is associated with vascular dementia. 9 38
16926537 2006
35
Apolipoprotein E epsilon4 allele frequency in vascular dementia. 9 38
16645276 2006
36
AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. 9 38
15990115 2005
37
CADASIL mutations impair Notch3 glycosylation by Fringe. 9 38
15857853 2005
38
Noninfarct vascular dementia and Alzheimer dementia spectrum. 9 38
15760616 2005
39
Blood cells cholinesterase activity in early stage Alzheimer's disease and vascular dementia. 9 38
15677868 2005
40
Absence of cholinergic deficits in "pure" vascular dementia. 9 38
15642917 2005
41
Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. 9 38
16192723 2005
42
[The effect of rivastigmine on cognitive functions and regional cerebral blood flow in Alzheimer's disease and vascular dementia: follow-up for 2 years]. 9 38
15654671 2004
43
Cholinesterase inhibition as a possible therapy for delirium in vascular dementia: a controlled, open 24-month study of 246 patients. 9 38
15633941 2004
44
[Vascular dementia]. 9 38
15224429 2004
45
Apolipoprotein E polymorphism in ischemic cerebrovascular diseases and vascular dementia patients in Taiwan. 9 38
15084782 2004
46
Immunoreactivities of amyloid beta peptide((1-42)) and total tau protein in lumbar cerebrospinal fluid of patients with normal pressure hydrocephalus. 9 38
14991454 2004
47
Apolipoprotein E gene polymorphism in Indian patients with Alzheimer's disease and vascular dementia. 9 38
14739533 2004
48
Common polymorphisms in methylenetetrahydrofolate reductase (MTHFR): relationships with plasma homocysteine concentrations and cognitive status in elderly northern italian subjects. 9 38
15207432 2004
49
Total tau in cerebrospinal fluid differentiates Alzheimer's disease from vascular dementia. 9 38
14586274 2003
50
Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy. 9 38
14561434 2003

Variations for Vascular Dementia

ClinVar genetic disease variations for Vascular Dementia:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 TNF NM_000594.3(TNF): c.-1037C> T single nucleotide variant risk factor rs1799724 6:31542482-31542482 6:31574705-31574705

Expression for Vascular Dementia

Search GEO for disease gene expression data for Vascular Dementia.

Pathways for Vascular Dementia

GO Terms for Vascular Dementia

Cellular components related to Vascular Dementia according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.84 CST3 BCHE APP APOE
2 membrane raft GO:0045121 9.8 TNF PSEN1 MAPT APP
3 neuron projection GO:0043005 9.8 PSEN1 NEFL MAPT CHAT APP
4 cell surface GO:0009986 9.8 VEGFA TNF PSEN1 MBP APP ACHE
5 blood microparticle GO:0072562 9.67 SERPINA3 PON1 BCHE APOE
6 extracellular space GO:0005615 9.65 VEGFA TNF SERPINA3 PON1 CST3 BCHE
7 platelet alpha granule lumen GO:0031093 9.63 VEGFA SERPINA3 APP
8 growth cone GO:0030426 9.56 PSEN1 NEFL MAPT APP
9 synaptic cleft GO:0043083 9.52 APOE ACHE
10 ciliary rootlet GO:0035253 9.51 PSEN1 APP
11 nuclear envelope lumen GO:0005641 9.48 BCHE APP
12 neuromuscular junction GO:0031594 9.46 PSEN1 NEFL APP ACHE
13 main axon GO:0044304 9.43 MAPT APP
14 extracellular region GO:0005576 9.4 VEGFA TNF SERPINA3 PON1 NOTCH3 MAPT

Biological processes related to Vascular Dementia according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.86 PSEN1 CST3 APP APOE
2 Notch signaling pathway GO:0007219 9.84 PSEN1 NOTCH3 APP
3 negative regulation of peptidase activity GO:0010466 9.84 SERPINA3 CST3 APP
4 positive regulation of protein phosphorylation GO:0001934 9.83 VEGFA TNF PSEN1 APP
5 response to toxic substance GO:0009636 9.81 PON1 NEFL MBP
6 cholesterol metabolic process GO:0008203 9.8 PON1 APP APOE
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.8 VEGFA TNF APP
8 forebrain development GO:0030900 9.77 PSEN1 NOTCH3 APP
9 positive regulation of protein binding GO:0032092 9.76 PSEN1 APP ACE
10 negative regulation of neuron apoptotic process GO:0043524 9.73 RETREG1 PSEN1 NEFL APOE
11 positive regulation of MAP kinase activity GO:0043406 9.72 VEGFA TNF PSEN1
12 microglial cell activation GO:0001774 9.67 TNF MAPT
13 synapse organization GO:0050808 9.67 PSEN1 MAPT APP
14 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.66 TNF APOE
15 axon development GO:0061564 9.65 NEFL MAPT
16 positive regulation of cholesterol efflux GO:0010875 9.65 PON1 APOE
17 neurotransmitter biosynthetic process GO:0042136 9.65 CHAT ACHE
18 amyloid-beta metabolic process GO:0050435 9.64 PSEN1 ACE
19 supramolecular fiber organization GO:0097435 9.63 MAPT CST3
20 negative regulation of gene expression GO:0010629 9.63 VEGFA TNF MAPT APP APOE ACE
21 neuron projection maintenance GO:1990535 9.62 PSEN1 APP
22 negative regulation of long-term synaptic potentiation GO:1900272 9.61 APP APOE
23 axonal transport of mitochondrion GO:0019896 9.61 NEFL MAPT
24 amyloid fibril formation GO:1990000 9.6 MAPT APP
25 response to folic acid GO:0051593 9.58 MTHFR BCHE
26 locomotion GO:0040011 9.57 PSEN1 NEFL
27 modulation of age-related behavioral decline GO:0090647 9.54 PSEN1 APP
28 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.51 PSEN1 APP
29 artery morphogenesis GO:0048844 9.5 VEGFA NOTCH3 APOE
30 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.48 PSEN1 APP
31 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.46 VEGFA ACE
32 amyloid precursor protein metabolic process GO:0042982 9.43 PSEN1 APOE ACHE
33 astrocyte activation involved in immune response GO:0002265 9.4 PSEN1 APP
34 smooth endoplasmic reticulum calcium ion homeostasis GO:0051563 9.37 PSEN1 APP
35 positive regulation of amyloid fibril formation GO:1905908 9.13 PSEN1 APP APOE
36 astrocyte activation GO:0048143 8.92 TNF PSEN1 MAPT APP

Molecular functions related to Vascular Dementia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidase inhibitor activity GO:0030414 9.58 SERPINA3 CST3 APP
2 protease binding GO:0002020 9.54 TNF MBP CST3
3 lipoprotein particle binding GO:0071813 9.32 MAPT APOE
4 identical protein binding GO:0042802 9.28 VEGFA TNF NOTCH3 NEFL MAPT CST3
5 cholinesterase activity GO:0004104 9.26 BCHE ACHE
6 amyloid-beta binding GO:0001540 9.26 CST3 BCHE APOE ACHE
7 acetylcholinesterase activity GO:0003990 9.16 BCHE ACHE

Sources for Vascular Dementia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....